Human milk oligosaccharides, brain structure, and cognitive development in infants: A narrative review
Ahmad Suryawan1, Chairunita2, Andy Darma1
1Department of Child Health, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia; Department of Child Health, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
Insights
Human milk oligosaccharides (HMOs) show potential for supporting infant brain development and cognitive function. Evidence suggests specific HMOs like 2-FL and sialylated HMOs may positively impact neurodevelopment, though more research is needed.
Area of Science:
- Neuroscience
- Nutritional Science
- Developmental Biology
Background:
- Human milk oligosaccharides (HMOs) are key bioactive components in breast milk.
- HMOs are known to influence gut microbiota and immune system development.
- Emerging evidence suggests a role for HMOs in early brain maturation and cognitive function.
Purpose of the Study:
- To review preclinical and clinical evidence on the association between HMOs and brain structure/neurodevelopment.
- To explore the biological mechanisms linking HMOs to brain outcomes.
- To identify knowledge gaps and future research directions.
Main Methods:
- A narrative review of studies identified through PubMed, Scopus, and Web of Science.
- Inclusion of animal and human studies examining HMOs and cognitive, behavioral, or neurobiological outcomes.
- Qualitative thematic synthesis of 18 selected studies.
Main Results:
- Preclinical studies suggest specific HMOs (e.g., 2'-FL, 3'-SL, 6'-SL) may enhance learning, memory, and emotional regulation.
- Proposed mechanisms include gut-brain signaling, microbiota modulation, and support for synaptogenesis/myelination.
- Human studies associate higher concentrations of certain HMOs with improved cognitive, language, motor, and executive functions, supported by MRI findings on brain maturation.
Conclusions:
- Current evidence suggests a potential role for HMOs in early neurodevelopment.
- Specific HMOs and their combinations may influence brain structure and function.
- Further large-scale longitudinal studies and RCTs are required to confirm causality and determine optimal HMO interventions.
Abstract:
Human milk oligosaccharides (HMOs) are bioactive components of human milk that support gut microbial development and may also contribute to early brain maturation and cognitive function. This narrative review aimed to synthesize preclinical and clinical evidence on the associations between HMOs, brain structure, and neurodevelopment and to examine the biological mechanisms underlying these effects. PubMed, Scopus, and Web of Science were searched in March 2025 for animal and human studies evaluating specific HMOs in relation to cognitive, behavioral, neurobiological, or neuroimaging outcomes. Of 1,238 records identified, 18 studies met the eligibility criteria and were included in a qualitative thematic synthesis. Preclinical studies indicated that 2'-fucosyllactose (2'-FL) and sialylated HMOs, including 3'-sialyllactose (3'-SL) and 6'-sialyllactose (6'-SL), may improve learning, memory, emotional regulation, and hippocampal long-term potentiation (LTP), although findings varied across experimental models. Proposed mechanisms included vagus nerve-mediated gut-brain signaling, modulation of the gut microbiota, altered neurotransmitter and neurotrophic signaling, and support of synaptogenesis and myelination. Human observational studies associated higher concentrations of 2'-FL, 3'-SL, 6'-SL, and specific HMO combinations during early lactation, particularly around one month postpartum, with better cognitive, language, motor, and executive-function outcomes. Magnetic resonance imaging (MRI) findings further suggested HMO-specific associations with cortical maturation, white-matter connectivity, and myelination. Current evidence supports a potential role for HMOs in early neurodevelopment; however, causal effects remain unconfirmed. Larger, diverse longitudinal studies and randomized controlled trials using standardized neurodevelopmental outcomes are needed to determine optimal HMO compositions, doses, and periods of exposure.
Related Concept Videos
Gut-Brain Axis
Development of the Oral Microbiota
Neurotransmitters


